Insulin oral - Unigene Laboratories

Drug Profile

Insulin oral - Unigene Laboratories

Latest Information Update: 04 Apr 2008

Price : $50

At a glance

  • Originator Unigene Laboratories
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 14 Aug 2003 No development reported - Preclinical for Type-1 diabetes mellitus in USA (PO)
  • 05 Jun 2001 Preclinical development for Type-1 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top